Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al

Detalles Bibliográficos
Autores principales: Viswanathan, Vidya Sankar, Khorrami, Mohammadhadi, Jazieh, Khalid, Fu, Pingfu, Pennell, Nathan, Madabhushi, Anant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157364/
https://www.ncbi.nlm.nih.gov/pubmed/35640931
http://dx.doi.org/10.1136/jitc-2022-005086
_version_ 1784718623226462208
author Viswanathan, Vidya Sankar
Khorrami, Mohammadhadi
Jazieh, Khalid
Fu, Pingfu
Pennell, Nathan
Madabhushi, Anant
author_facet Viswanathan, Vidya Sankar
Khorrami, Mohammadhadi
Jazieh, Khalid
Fu, Pingfu
Pennell, Nathan
Madabhushi, Anant
author_sort Viswanathan, Vidya Sankar
collection PubMed
description
format Online
Article
Text
id pubmed-9157364
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91573642022-06-16 Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al Viswanathan, Vidya Sankar Khorrami, Mohammadhadi Jazieh, Khalid Fu, Pingfu Pennell, Nathan Madabhushi, Anant J Immunother Cancer Letter BMJ Publishing Group 2022-05-31 /pmc/articles/PMC9157364/ /pubmed/35640931 http://dx.doi.org/10.1136/jitc-2022-005086 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.
spellingShingle Letter
Viswanathan, Vidya Sankar
Khorrami, Mohammadhadi
Jazieh, Khalid
Fu, Pingfu
Pennell, Nathan
Madabhushi, Anant
Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al
title Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al
title_full Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al
title_fullStr Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al
title_full_unstemmed Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al
title_short Response to: Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Zheng et al
title_sort response to: correspondence on 'novel imaging biomarkers predict outcomes in stage iii unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by zheng et al
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157364/
https://www.ncbi.nlm.nih.gov/pubmed/35640931
http://dx.doi.org/10.1136/jitc-2022-005086
work_keys_str_mv AT viswanathanvidyasankar responsetocorrespondenceonnovelimagingbiomarkerspredictoutcomesinstageiiiunresectablenonsmallcelllungcancertreatedwithchemoradiationanddurvalumabbyzhengetal
AT khorramimohammadhadi responsetocorrespondenceonnovelimagingbiomarkerspredictoutcomesinstageiiiunresectablenonsmallcelllungcancertreatedwithchemoradiationanddurvalumabbyzhengetal
AT jaziehkhalid responsetocorrespondenceonnovelimagingbiomarkerspredictoutcomesinstageiiiunresectablenonsmallcelllungcancertreatedwithchemoradiationanddurvalumabbyzhengetal
AT fupingfu responsetocorrespondenceonnovelimagingbiomarkerspredictoutcomesinstageiiiunresectablenonsmallcelllungcancertreatedwithchemoradiationanddurvalumabbyzhengetal
AT pennellnathan responsetocorrespondenceonnovelimagingbiomarkerspredictoutcomesinstageiiiunresectablenonsmallcelllungcancertreatedwithchemoradiationanddurvalumabbyzhengetal
AT madabhushianant responsetocorrespondenceonnovelimagingbiomarkerspredictoutcomesinstageiiiunresectablenonsmallcelllungcancertreatedwithchemoradiationanddurvalumabbyzhengetal

Ejemplares similares